TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Science

    FirstTake on Pharma – Pharma News and Analysis Podcast

    The FirstTake – FirstWord’s editors discuss the latest pharma news and offer insights from industry experts and KOLs. Designed for the busy pharma industry professional. Visit us at beta.firstwordpharma.com to sign up for newsletters delivering timely news and event-driven physician intelligence.

    Advertise

    Copyright: © 2021

    • Apple Podcasts
    • Google Play
    • Spotify
    Latest Episodes:
    The FirstTake Podcast – Intellia presents an important gene-editing breakthrough Jul 01, 2021
    Show notes

    FirstWord Pharma PLUS editors Becky Simon, Michael Flanagan and Simon King discuss Sanofi’s investment in mRNA vaccines, breakthrough data for Intellia Therapeutics’ gene editing therapy NLTA-2001, the ongoing uncertainty around JAK inhibitors and whether CAR-T therapies are primed for earlier-line use.

    The FirstTake Podcast – Eli Lilly makes regulatory U turn with Alzheimer’s hopeful Jun 24, 2021
    Show notes

    FirstWord Pharma PLUS editors Becky Simon, Michael Flanagan and Simon King discuss Eli Lilly’s decision to file its investigational Alzheimer’s disease treatment donanemab for accelerated approval with the FDA, take a closer look at Intellia Therapeutics’ pivot into CAR-T, question whether momentum is building for Big Pharma in-licensing deals and break down expert feedback on Sage Therapeutics depression drug zuranolone.

    The FirstTake Podcast – GSK targets iTeos to advance its TIGIT aspirations Jun 17, 2021
    Show notes

    Earlier this week GlaxoSmithKline announced it will pay iTeos Therapeutics $625 million dollars upfront to gain exclusive co-marketing rights for the latter’s anti-TIGIT monoclonal antibody EOS-448, as part of a deal potentially worth over $2 billion. The drug is currently in Phase I development for advanced solid tumours and this collaboration represents the latest move by GlaxoSmithKline to build out its cancer pipeline. FirstWord Pharma PLUS executive editor Simon King spoke to Jo Jenkins, chief medical officer at iTeos about the deal, EOS-448 and the competitive anti-TIGIT field where the likes of Roche, Merck & Co. and Bristol Myers Squibb are all active.

    The FirstTake Podcast – FirstWord’s editors discuss the controversial approval of Biogen’s Aduhelm Jun 10, 2021
    Show notes

    FirstWord Pharma PLUS editors Becky Simon, Michael Flanagan and Simon King discuss FDA approval of the first potentially disease modifying Alzheimer’s disease treatment Aduhelm (aducanumab), which has dominated industry headlines this week. Simon also speaks to EQRx President and Chief Operating Office Melanie Nallicheri about the company’s aspirations to disrupt pharmaceutical pricing and what describes as its “data coming out part” at ASCO this past weekend.

    The FirstTake Podcast – KRAS, OX40, EQRx and ASCO in focus Jun 03, 2021
    Show notes

    FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss FDA approval of the first KRAS inhibitor – Amgen’s Lumakras, the emergence of OX40 as an increasingly sought after target for investigational atopic dermatitis treatments, more clinical data to support EQRx’s price-disruptive push into oncology and look ahead to this weekend’s virtual ASCO meeting.

    The FirstTake Podcast – Will vaccine sales prime Pfizer for deal-making? May 27, 2021
    Show notes

    FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss whether soaring revenue projections for Pfizer’s COVID-19 vaccine will position the company as an aggressive deal-maker, assess yet another setback in the once-promising field of NASH and cast an eye over the potential opportunity for Cabometyx as a new treatment option for prostate cancer.

    The FirstTake Podcast – ASCO abstracts drop May 20, 2021
    Show notes

    FirstWord Pharma PLUS editors Michael Flanagan, Simon King and Becky Simon discuss high profile clinical datasets which were released on Wednesday in abstract form ahead of this year’s virtual annual meeting of the American Society of Clinical Oncology (ASCO) which will be held on June 4-8.

    The FirstTake Podcast – Face to face meetings between drug sales reps and docs continue to creep upwards May 13, 2021
    Show notes

    FirstWord Pharma PLUS editors Michael Flanagan, Simon King and Becky Simon discuss the latest COVID-19 vaccine headlines; look at biotech collaborations signed this week by Biogen and Eli Lilly; and highlight results from a new FirstWord survey showing that a steady increase in face-to-face interactions between pharma companies and physicians as accelerated since the turn of the year.

    The FirstTake Podcast – How much? – Pfizer reveals COVID-19 vaccine sales forecast May 06, 2021
    Show notes

    FirstWord Pharma PLUS editors Simon King and Becky Simon discuss Pfizer and Moderna’s COVID-19 vaccine revenue forecasts for the year ahead, controversy around the potential lifting of intellectual property protection on COVID-19 vaccines and new, early-stage data for Sarepta Therapeutics’ latest Duchene muscular dystrophy therapy.

    The FirstTake Podcast – Deucravacitinib delivers as Big Pharma endures a tough Q1 Apr 29, 2021
    Show notes

    FirstWord Pharma PLUS editors Michael Flanagan, Simon King and Becky Simon discuss new Phase III data for Bristol Myers Squibb’s first-in-class psoriasis treatment deucravacitinib, the impact of the COVID-19 pandemic on Big Pharma’s first quarter performance and this week’s FDA AdCom meeting on accelerated cancer drug approvals.

    Previous 1 2 3 4 5 6 Next

    Related Podcasts

    Invisibilia

    1

    Invisibilia Personal Journals
    Hidden Brain – Hidden Brain, Shankar Vedantam

    2

    Hidden Brain – Hidden Brain, Shankar Vedantam Science
    How To Do Everything

    3

    How To Do Everything Science
    Hidden Brain

    4

    Hidden Brain Games & Hobbies
    Something You Should Know

    5

    Something You Should Know Education
    Sword and Scale – Sword and Scale

    6

    Sword and Scale – Sword and Scale Alternative Health
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights